Should we screen asymptomatic individuals for coronary artery disease or implement universal lipid-lowering therapy?

Cardiology in Review

Volumn 13, Issue 1, 2005, Pages 40-45

  Thomas, Gregory S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cholesterol; Coronary disease; Heart diseases; Mass screening; Practice guidelines; Tomographies; X ray computed

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JJT 705; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; ELECTRON BEAM TOMOGRAPHY; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESPAN; LIFESTYLE; MENOPAUSE; OUTCOMES RESEARCH; PATIENT CARE; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SYMPTOMATOLOGY; TREATMENT INDICATION;

ADULT; ANTILIPEMIC AGENTS; CHEMOPREVENTION; CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 13444302624     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000134646.52262.05     Document Type: Review

References (43)

1. National Center for Health Statistics. National Vital Statistics Reports, vol 52, no 3, September 18, 2003. Available at: www.cdc.gov/nchs/fastats/ deaths.htm. Accessed March 28, 2004.
2. Pasternak RC, Abrams J, Greenland P, et al. Task Force #1 - identification of coronary heart disease risk: is there a detection gap? J Am Coll Cardiol. 2003;41:1863-1874.
3. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. September 14-15, 1995. J Am Coll Cardiol. 1996;27:957-1047.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
5. Lenfant C. Clinical research to clinical practice - lost in the translation. N Engl J Med. 2003;349:868-873.
6. Fowler-Brown A, Pignone M, Pletcher M. Summary of the evidence: exercise tolerance testing to screen for coronary heart disease. February 2004. Available at: www.ahcpr.gov/clinic/3rduspstf/chd/chdsum1.htm. Accessed March 28, 2004.
7. Shaw LJ, Raggi P, Schisterman E, et al. Prognostic value of cardiac risk factors and coronary artery screening for all-cause mortality. Radiology. 2003;228:826-833.
8. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period often years in patients with peripheral arterial disease. N Engl J Med. 1992; 326:381-386.
9. Bots ML, Hoes AW, Koudstall PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam study. Circulation. 1997;96:1432-1437.
10. Greenland P, Smith JS Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001;104:1863-1867.
11. Gordis L. Epidemiology, 2nd ed. Philadelphia: WB Saunders; 2000:64-66.
12. Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med. 2000;343:16-22.
13. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160: 459-467.
14. Lloyd-Jones DM, Larson MG, Besier A, et al. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89-92.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
16. American Heart Association. Cardiovascular Disease Cost. Available at: www.americanheart.org/presenter.jhtml?identifier=4475. Accessed March 28, 2004.
17. Cannon C, Braunwald E, McCabe. Comparison of intensive vs. moderate lipid lowering with statins after acute coronary symptoms. N Engl J Med. 2004;350. April 15, 2004. Available at: www.nejm.org. Accessed March 9, 2004.
18. Nissan SE, Tuzcu EM, Schoenhagen, et al. Effect of intensive compared with moderate lipid-lowering on progression of atherosclerosis. JAMA. 2004;291:1071-1080.
19. Downs JR, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
20. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
21. Young CT, Karas JT, Kuven RH. High density lipoprotein cholesterol and coronary heart disease. Cardiol Rev. 2004;12:107-119.
22. Brown BG, Xue-Qiao A, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1589.
23. IMS New Script Market Shares. Fairfield, CT: IMS Health; February 2004.
24. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis [Letter]. N Engl J Med. 2002;346:539-540.
25. Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol. 2002;90(suppl):50K-60K.
26. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108: 538-546.
27. Yaffe K, Barrett-Connor E, Lin R, et al. Serum lipoprotein levels, statin use and cognitive function in older women. Arch Neurol. 2002;59:378-384.
28. Wagstaff LR, Mitton MW, Arvik BM, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23:871-880.
29. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 2001;103:2705-2710.
30. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419.
31. Morrison AS. Screening in Chronic Disease, Monographs in Epidemiology and Biostatistics, 2nd ed. Oxford: Oxford University Press; 1992.
32. Wilson PWF, Smith SC Jr, Blumenthal, et al. Task Force #4 - how do we select patients for atherosclerosis imaging. J Am Coll Cardiol. 2003;41:1898-1906.
33. Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham risk score for risk reduction in asymptomatic individuals. JAMA. 2004;291:210-215.
34. Hunold P, Vogt FM, Schmermund A, et al. Radiation exposure during cardiac CT: effective doses at multi-detector row CT and electron beam CT. Radiology. 2003;226:145-152.
35. Elgin EE, O'Malley PG, Feurstein AJ, et al. Frequency and severity of 'incidentalomas' encountered during electron beam computed tomography for coronary calcium in middle-aged army personnel. Am J Cardiol. 2002;90:543-544.
36. Hunold P, Schmermund A, Seibel RM, et al. Prevalence and clinical significance of accidental findings in electron beam tomographic scans for coronary artery calcification. Eur Heart J. 2001;22:1748-1758.
37. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA guidelines for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol. 1999;34:1262-1346.
38. Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol. 2001;37: 2239I-lxvi.
39. Mieres JH, Shaw LJ. Stress myocardial perfusion imaging in the diagnosis and prognosis of women with suspected coronary artery disease. Cardiol Rev. 2003;11:330-336.
40. Hachamovitch R, Hayes S, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation. 2003;107:2900-2906.
41. The Peace Trial Investigators. Angiotension-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-2068.
42. O'Keefe JH Jr, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142-2146.
43. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.